Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070985 | 0.95 | DDB1 (0.48) | DDB1CRBNIKZF3 | |
| SCHEMBL21071255 | 0.88 | DDB1 (0.48) | DDB1CRBNSTAT3 | |
| SCHEMBL21107858 | 0.87 | DDB1 (0.47) | DDB1CRBNSTAT3 | |
| SCHEMBL21997419 | 0.83 | DDB1 (0.42) | DDB1CRBNIKZF3 | |
| Hydrochloric Acid SCHEMBL34464129 | 0.83 | DDB1 (0.42) | DDB1CRBNIKZF3 | |
| SCHEMBL21070581 | 0.82 | DDB1 (0.45) | DDB1CRBNSTAT3 | |
| SCHEMBL25370255 | 0.82 | CRBN (0.45) | DDB1CRBNIKZF3 | |
| SCHEMBL21069341 | 0.81 | DDB1 (0.63) | DDB1CRBNIKZF3 | |
| SCHEMBL20840368 | 0.81 | DDB1 (0.63) | DDB1CRBNIKZF3 | |
| SCHEMBL25122888 | 0.81 | DDB1 (0.63) | DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | DDB1 269/4885CRBN 93/4885IKZF3 356/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.